Overview

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment

Status:
Enrolling by invitation
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of DBPR108 in subjects with mild, moderate, severe renal impairment and subjects with kidney failure compared to the matched control subjects with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.